List of Excipients in Branded Drug UPTRAVI

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actelion Pharmaceuticals US Inc	UPTRAVI	selexipag	66215-602	CARNAUBA WAX
Actelion Pharmaceuticals US Inc	UPTRAVI	selexipag	66215-602	FERRIC OXIDE YELLOW
Actelion Pharmaceuticals US Inc	UPTRAVI	selexipag	66215-602	HYDROXYPROPYL CELLULOSE

UPTRAVI Excipient Strategy and Commercial Opportunities in Pulmonary Arterial Hypertension

Last updated: October 17, 2026

UPTRAVI (selexipag) uses a conventional immediate-release tablet platform built around direct compression or low-moisture granulation excipients, with a separate lyophilized or powder-for-reconstitution strategy for intravenous administration. The commercial opportunity is strongest in low-dose, high-potency handling, taste and dose-uniformity technologies, injectable excipients, and generic-ready manufacturing services. UPTRAVI’s differentiated value comes primarily from selexipag pharmacology, dosing flexibility, and the active metabolite ACT-333679, rather than from an unusually complex oral excipient system.

What is UPTRAVI and which formulations are commercially relevant?

UPTRAVI is an oral and intravenous selexipag product developed for adults with pulmonary arterial hypertension (PAH), WHO Functional Class II to III, to delay disease progression and reduce hospitalization risk for worsening PAH. Actelion Pharmaceuticals, now part of Johnson & Johnson, developed and commercialized the product.

Product attribute	Oral UPTRAVI	Intravenous UPTRAVI
Active ingredient	Selexipag	Selexipag
Primary use	Chronic maintenance treatment	Temporary replacement when oral administration is not feasible
Dosage form	Film-coated tablet	Powder or sterile product for reconstitution
Dosing flexibility	200 mcg twice daily titrated in 200 mcg increments	Dose conversion based on oral regimen and clinical need
Administration	Oral	Intravenous infusion after reconstitution
Key formulation challenge	Uniformity at microgram-to-low-milligram dose levels	Sterility, solubility, stability and infusion compatibility
Commercial role	Core chronic therapy	Hospital and specialty-care support product

The oral tablets are marketed in multiple strengths, including 200 mcg through 1,600 mcg, allowing titration according to tolerability. The low active-load-to-tablet-mass ratio makes blend uniformity and segregation control central to manufacturing performance.

What excipients are used in UPTRAVI tablets?

The US prescribing information identifies a standard solid-dose excipient system for UPTRAVI tablets. The inactive ingredients include mannitol, corn starch, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, and magnesium stearate. The film coating contains hypromellose, titanium dioxide, triacetin, and colorants, including iron oxides depending on tablet strength.[1]

Excipient	Likely formulation function	Commercial relevance
Mannitol	Diluent and bulking agent	Supports tablet mass, mouthfeel and low-dose dose uniformity
Corn starch	Disintegrant and filler	Helps tablet breakup and manufacturability
Low-substituted hydroxypropyl cellulose	Disintegrant and matrix-forming aid	Supports rapid disintegration and mechanical integrity
Hydroxypropyl cellulose	Binder	Controls granule strength and tablet robustness
Magnesium stearate	Lubricant	Reduces ejection force and tooling friction
Hypromellose	Film former	Provides coating protection and appearance
Titanium dioxide	Opacifier and white pigment	Controls coating opacity and visual uniformity
Triacetin	Plasticizer	Improves coating flexibility and reduces cracking
Iron oxides	Colorants	Distinguish strengths and support product identification

The formulation is commercially attractive to generic manufacturers because the excipient set is widely available and is not dependent on a novel delivery technology. The principal technical burden is the small quantity of selexipag relative to total tablet weight and the need to maintain dose proportionality across several strengths.

How does the UPTRAVI excipient strategy support dose uniformity?

Selexipag is administered at microgram-to-low-milligram doses, while the tablet contains a much larger excipient mass. This creates a classic low-dose blend-uniformity problem.

Mannitol provides bulk and can support a consistent powder bed. Corn starch and low-substituted hydroxypropyl cellulose support rapid tablet disintegration. Hydroxypropyl cellulose improves granule cohesion, which reduces friability and helps maintain tablet integrity during packaging and transport. Magnesium stearate must be controlled carefully because over-lubrication can reduce tablet tensile strength, slow dissolution, or interfere with powder wetting.

The principal process controls are likely to include:

• Geometric dilution or ordered blending of selexipag with the diluent system.
• Control of particle-size distribution and density differences.
• Narrow blend-time windows to limit segregation and overmixing.
• In-process sampling across the blender and tablet press.
• Compression-force control across all strengths.
• Dissolution testing that confirms rapid release after disintegration.
• Packaging controls that limit moisture and mechanical attrition.

A generic applicant may choose the same excipients but use a different process, grade, particle-size distribution, or compression profile. Excipients listed in the reference product label do not automatically require exact supplier or grade matching.

What commercial opportunities exist for excipient suppliers?

The strongest opportunities are in established excipients with pharmaceutical-grade supply, low-metal impurity profiles, and documented performance in low-dose oral products.

Mannitol and direct-compression diluents

Mannitol suppliers can target:

• Direct-compression grades with controlled flow.
• Low-bioburden and low-endotoxin grades for broader formulation platforms.
• Particle-engineered grades designed to reduce segregation.
• Co-processed mannitol systems that improve compactability.

A supplier that can demonstrate improved blend uniformity for low-dose APIs has a stronger commercial position than a commodity supplier offering only standard mannitol.

Cellulose-based binders and disintegrants

Hydroxypropyl cellulose and low-substituted hydroxypropyl cellulose are established products with multiple supplier sources. Differentiation can come from:

• Consistent substitution levels.
• Controlled particle morphology.
• Faster hydration and disintegration.
• Reduced variability across production sites.
• Documentation supporting global regulatory filings.

The opportunity is not limited to UPTRAVI. The same excipient technology applies to other potent cardiovascular, oncology and central-nervous-system products that require low-dose content uniformity.

Lubricant systems

Magnesium stearate is a mature category, but lubricant quality can affect tablet ejection, dissolution and stability. Suppliers may create value through:

• Narrow particle-size specifications.
• Low-moisture grades.
• Better dispersion during short blending cycles.
• Lubricant systems that reduce hydrophobic film formation.
• Data packages addressing elemental impurities and nitrosamine risk.

Film-coating systems

UPTRAVI’s multiple strengths create a need for reliable color differentiation and coating uniformity. Commercial opportunities include pre-mixed film-coating systems that reduce batch-to-batch variability and simplify color matching across manufacturing sites.

What excipients are relevant to intravenous UPTRAVI?

The intravenous formulation has a different risk profile from the oral tablet. Its critical quality attributes are sterility, reconstitution time, solution clarity, pH, osmolality, chemical stability and compatibility with infusion materials.

The US labeling for UPTRAVI for injection identifies arginine and phosphoric acid among the formulation components, with sterile water used for reconstitution or preparation according to the prescribing instructions.[2] Arginine can support solubilization and pH control, while phosphoric acid provides pH adjustment.

Injectable requirement	Excipient or platform opportunity
Solubility	Amino-acid-based solubilization systems
pH control	Phosphate and other low-reactivity buffers
Sterility	Sterile excipient supply and aseptic manufacturing
Reconstitution	Rapid-dissolving cake or powder design
Infusion compatibility	Low-sorbtion container and tubing systems
Stability	Low-peroxide, low-metal impurity excipient grades

The injectable product creates a higher barrier to entry than the oral tablet because an abbreviated applicant must control sterile manufacturing, container-closure integrity, reconstitution performance, and compatibility with hospital infusion equipment.

What patents protect UPTRAVI and its formulation?

UPTRAVI’s patent position is likely broader than its listed excipients. The relevant protection categories include:

1. Selexipag composition-of-matter patents.
2. Active-metabolite or therapeutic-use claims.
3. Methods of treating PAH with selexipag.
4. Dosing and titration regimens.
5. Pharmaceutical compositions containing selexipag.
6. Solid-state, purity, salt or polymorph claims where applicable.
7. Intravenous formulations and reconstitution methods.
8. Manufacturing processes and intermediates.

The excipients named in the FDA label are generally standard compendial materials. A competitor is unlikely to face a meaningful exclusivity barrier merely because UPTRAVI uses mannitol, starch, hydroxypropyl cellulose and magnesium stearate. The more relevant question is whether an issued formulation or process patent claims a specific combination, ratio, particle-size range, manufacturing step, or dosage form.

The Orange Book remains the controlling public source for FDA-listed patents and exclusivity information for approved small-molecule products.[3] Orange Book listings should be distinguished from the full patent estate. Unlisted patents may still affect manufacturing, intermediates, international markets or litigation strategy, while listed patents may not cover every commercially relevant design-around.

When does UPTRAVI lose exclusivity?

UPTRAVI received US FDA approval in December 2015.[4] Its commercial exclusivity is governed by a combination of patent rights, regulatory exclusivity, pediatric provisions and any later-listed patents for additional formulations.

For a generic applicant, the practical entry date depends on:

• The earliest enforceable expiration of relevant listed patents.
• Any pediatric exclusivity extension.
• Whether the applicant files a Paragraph IV certification.
• The date of FDA acceptance of the abbreviated new drug application.
• Whether the reference sponsor brings litigation within the statutory period.
• The outcome or settlement terms of the litigation.
• Whether the generic seeks all strengths or a limited commercial package.

A precise launch date cannot be inferred from the original approval date alone. Small-molecule products can face staggered entry through separate patents covering the active ingredient, formulation, method of use or injectable presentation.

Are there Paragraph IV challenges to UPTRAVI?

A Paragraph IV challenge would require a generic applicant to assert that one or more Orange Book-listed patents are invalid, unenforceable or not infringed. The FDA cannot approve an ANDA with a Paragraph IV certification until the applicable statutory framework is satisfied, including the 30-month litigation stay if the sponsor files suit within the required period.[5]

For UPTRAVI, the likely challenge points would include:

• Non-infringement through a different excipient ratio or manufacturing process.
• Invalidity based on obviousness for routine oral formulation features.
• Lack of enablement or written description for broad formulation claims.
• Expiration or inapplicability of method-of-use claims.
• Carve-outs for PAH indications or dosing instructions.
• Alternative injectable presentation designs.

The commercial risk is higher if the key patents cover selexipag itself or a required active form. It is lower if the remaining patents cover only a narrow tablet composition that can be designed around without compromising bioequivalence.

What is the FDA regulatory status of UPTRAVI?

UPTRAVI is an FDA-approved prescription drug for PAH. Its regulatory profile includes:

• New drug application approval for oral tablets.
• Multiple tablet strengths to support individualized titration.
• A later intravenous presentation for patients unable to take the oral product.
• A specialized risk-benefit profile involving tolerability-driven dose adjustment.
• Small-molecule generic pathway through ANDA submission rather than a biosimilar pathway.

Biosimilar risk does not apply because selexipag is a chemically synthesized small molecule, not a biologic. Competitive pressure will come from generics, authorized-generic strategies, alternative PAH therapies and hospital substitution for the injectable product.

Which companies compete with UPTRAVI?

UPTRAVI competes in a PAH market that includes prostacyclin-pathway therapies and other pathway-directed products.

Product	Active ingredient	Company or originator	Competitive relationship
UPTRAVI	Selexipag	Johnson & Johnson/Actelion	Oral prostacyclin receptor agonist
Orenitram	Treprostinil	United Therapeutics	Oral prostacyclin analogue
Tyvaso	Treprostinil	United Therapeutics	Inhaled prostacyclin analogue
Remodulin	Treprostinil	United Therapeutics	Injectable prostacyclin analogue
Veletri	Epoprostenol	Sandoz/legacy GSK	Intravenous prostacyclin
Flolan	Epoprostenol	Legacy GlaxoSmithKline	Intravenous prostacyclin
Tracleer	Bosentan	Johnson & Johnson/Actelion	Endothelin-receptor antagonist
Opsumit	Macitentan	Johnson & Johnson/Actelion	Endothelin-receptor antagonist
Adcirca	Tadalafil	Eli Lilly/United Therapeutics	PDE-5 inhibitor
Alyq	Tadalafil	Teva	Genericized tadalafil PAH product

The closest formulation comparison is Orenitram, another oral prostacyclin-pathway product, but its extended-release technology creates a different excipient and patent profile. UPTRAVI’s immediate-release titration platform may be easier to reproduce technically, while Orenitram’s controlled-release system may create more complex bioequivalence and formulation barriers.

How strong is the UPTRAVI patent estate?

UPTRAVI’s estate is commercially meaningful because it can combine active-ingredient, use, dosing, formulation and injectable-product rights. Its strength depends on the remaining term and claim scope of each patent family.

Patent category	Likely strength	Generic risk
Active ingredient	High if unexpired and valid	Low before expiry; high after expiry
PAH method of use	Moderate	Can be bypassed through labeling strategy
Dose-titration claims	Moderate	Depends on claim breadth and prescribing practice
Standard tablet excipients	Low to moderate	Usually design-around capable
Specific formulation ratios	Moderate	May support Paragraph IV litigation
Injectable formulation	Moderate to high	Sterile and compatibility barriers increase risk
Manufacturing process	Variable	Often avoidable with alternate processes

The commercial exposure is substantial because UPTRAVI is a high-value specialty product. Johnson & Johnson reported more than $1 billion in annual global sales for UPTRAVI in recent reporting periods, making generic entry strategically important to the sponsor and to potential ANDA filers.[6]

What generic launch scenarios exist for UPTRAVI?

Scenario 1: At-risk launch

A generic launches after filing Paragraph IV certifications but before final patent resolution. This can create damages exposure, an injunction risk and rapid price erosion. The strategy is most likely when the challenger has a strong invalidity or non-infringement position and the remaining market opportunity is large.

Scenario 2: Negotiated entry

The sponsor and generic applicant settle litigation with a delayed entry date, licensed launch, supply arrangement or other permitted commercial structure. The value of the agreement depends on the remaining patent term, the number of challengers and the strength of the generic’s case.

Scenario 3: Post-expiry launch

The generic waits for patent expiry and avoids litigation. This reduces legal cost but allows competing applicants to prepare launches and may reduce first-filer economics.

Scenario 4: Limited-strength or indication launch

A generic may initially seek selected strengths or use a label that omits protected indications. This can reduce litigation risk but may limit substitution and payer uptake.

What manufacturing and IP barriers matter most?

For oral UPTRAVI, the principal manufacturing barriers are low-dose uniformity, segregation control, dissolution reproducibility and multi-strength scale-up. These are manageable with conventional technology but require strong process validation.

For intravenous UPTRAVI, the barriers are higher:

• Sterile powder or solution manufacture.
• Control of endotoxin and particulate matter.
• Reconstitution performance.
• Stability after preparation.
• Infusion-line compatibility.
• Container-closure integrity.
• Hospital-use instructions and pharmacy handling.

The best commercial opportunities therefore sit between commodity excipient supply and specialized formulation services. Suppliers that combine excipient materials with process data, analytical methods and regulatory documentation can capture more value than suppliers selling individual ingredients.

Key Takeaways

• UPTRAVI is selexipag, a small-molecule PAH therapy marketed primarily as a multi-strength immediate-release tablet.
• The oral formulation uses conventional excipients: mannitol, corn starch, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose and magnesium stearate, with a hypromellose-based film coating.
• The principal oral formulation challenge is dose uniformity at a microgram-to-low-milligram active load.
• Injectable UPTRAVI creates higher-value opportunities in sterile excipients, solubilization, pH control, reconstitution and infusion compatibility.
• Standard excipients are unlikely to create a significant standalone patent barrier. Active-ingredient, formulation, dosing, method-of-use and injectable patents matter more.
• Generic competition will follow the Orange Book patent and exclusivity timeline, Paragraph IV activity and any settlement agreements.
• Biosimilars are not relevant because selexipag is a chemically synthesized small molecule.
• Commercial opportunity is strongest for particle-engineered mannitol, high-consistency cellulose excipients, advanced film coatings and sterile injectable formulation platforms.

FAQs

Can a generic UPTRAVI use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the formulation meets applicable safety, pharmaceutical equivalence, bioequivalence, quality and labeling requirements. The applicant must address any differences that could affect absorption, tolerability or performance.

Is UPTRAVI an extended-release tablet?

No. UPTRAVI is marketed as an immediate-release oral tablet. Its dose is titrated upward according to tolerability rather than delivered through a controlled-release matrix.

Does UPTRAVI require a biosimilar application?

No. Selexipag is a chemically synthesized small molecule. A competing oral product would generally use the ANDA pathway, subject to pharmaceutical-equivalence and bioequivalence requirements.

Which UPTRAVI excipient has the greatest formulation value?

Mannitol is important because it supplies bulk for a very low-dose API, but low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose also materially affect disintegration, binding and tablet robustness. The commercial value lies in the combined formulation and process, not in one excipient alone.

Is the injectable UPTRAVI formulation easier to copy than the tablet?

No. The injectable formulation introduces sterile manufacturing, reconstitution, stability, container-closure and infusion-compatibility requirements. Those factors can create greater technical and regulatory barriers than the oral tablet.

References

1. U.S. Food and Drug Administration. (2024). UPTRAVI (selexipag) tablets, prescribing information.
2. U.S. Food and Drug Administration. (2024). UPTRAVI for injection (selexipag), prescribing information.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2015). FDA approves Uptravi to treat pulmonary arterial hypertension.
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and Paragraph IV certifications.
6. Johnson & Johnson. (2024). Annual report and full-year financial results.